Recent advances in the characterization of HIV-1 neutralization assays for standardized evaluation of the antibody response to infection and vaccination.

Published

Journal Article (Review)

In AIDS vaccine development the pendulum has swung towards a renewed emphasis on the potential role for neutralizing antibodies in a successful global vaccine. It is recognized that vaccine-induced antibody performance, as assessed in the available neutralization assays, may well serve as a "gatekeeper" for HIV-1 subunit vaccine prioritization and advancement. As a result, development of a standardized platform for reproducible measurement of neutralizing antibodies has received considerable attention. Here we review current advancements in our knowledge of the performance of different types of antibodies in a traditional primary cell neutralization assay and the newer, more standardized TZM-bl reporter cell line assay. In light of recently revealed differences (see accompanying article) in the results obtained in these two neutralization formats, parallel evaluation with both platforms should be contemplated as an interim solution until a better understanding of immune correlates of protection is achieved.

Full Text

Duke Authors

Cited Authors

  • Polonis, VR; Brown, BK; Rosa Borges, A; Zolla-Pazner, S; Dimitrov, DS; Zhang, M-Y; Barnett, SW; Ruprecht, RM; Scarlatti, G; Fenyö, E-M; Montefiori, DC; McCutchan, FE; Michael, NL

Published Date

  • June 2008

Published In

Volume / Issue

  • 375 / 2

Start / End Page

  • 315 - 320

PubMed ID

  • 18367229

Pubmed Central ID

  • 18367229

Electronic International Standard Serial Number (EISSN)

  • 2514-4138

International Standard Serial Number (ISSN)

  • 1096-0341

Digital Object Identifier (DOI)

  • 10.1016/j.virol.2008.02.007

Language

  • eng